Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial

  • The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity Inc VAXX will co-fund the ongoing global Phase 3 trial of Vaxxinity's next-generation UB-612 COVID-19 vaccine candidate.
  • The candidate is under development as a heterologous – or 'mix-and-match' – booster dose. 
  • CEPI will provide up to $9.25 million in funding.
  • The Phase 3 trial, which began in the US earlier this year, is evaluating UB-612 to boost COVID-19 immunity against the original strain and multiple variants.
  • The trial includes people aged 16 years or older who have been previously immunized with an authorized COVID-19 vaccine. 
  • Approximately 1,000 healthy adults will participate in the Vaxxinity-sponsored multi-center international trial. 
  • The primary immunogenicity analyses will be available in 2H of 2022. 
  • If successful, the study may support conditional approval of UB-612, as discussed with global regulators.
  • UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, which is designed to activate the immune system's B and T-cell arms. 
  • Phase 1 and Phase 2 trials of UB-612 conducted in ~4000 participants have shown UB-612 to be well tolerated with no vaccine-related serious adverse events.
  • Price Action: VAXX shares closed 5.02% lower at $4.35 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!